20.500.12556/DiRROS-19832 Bleomycin electrosclerotherapy (BEST) for the treatment of vascular malformations an International Network for Sharing Practices on Electrochemotherapy (InspECT) study group report Biomedical applications of electroporation are expanding out of the field of oncology into vaccination, treatment of arrhythmias and now in the treatment of vascular malformations. Bleomycin is a widely used sclerosing agent in the treatment of various vascular malformations. The application of electric pulses in addition to bleomycin enhances the effectiveness of the drug, as demonstrated by electrochemotherapy, which utilizes bleomycin in the treatment of tumors. The same principle is used in bleomycin electrosclerotherapy (BEST). The approach seems to be effective in the treatment of low-flow (venous and lymphatic) and, potentially, even high-flow (arteriovenous) malformations. Although there are only a few published reports to date, the surgical community is interested, and an increasing number of centers are applying BEST in the treatment of vascular malformations. Within the International Network for Sharing Practices on Electrochemotherapy (InspECT) consortium, a dedicated working group has been constituted to develop standard operating procedures for BEST and foster clinical trials. By treatment standardization and successful completion of clinical trials demonstrating the effectiveness and safety of the approach, higher quality data and better clinical outcomes may be achieved. vascular malformations electrosclerotherapy bleomycin žilne malformacije elektroskleroterapija bleomycin true false true Association of Radiology and Oncology Ljubljana Angleški jezik Slovenski jezik by Authors Neznano 2024-07-25 14:12:14 2024-07-25 14:12:14 2026-06-17 12:44:21 0000-00-00 00:00:00 2023 0 0 str. 141-149 no. 2 Vol. 57 2023 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 2023-01-01 616-006 1318-2099 10.2478/raon-2023-0029 159007235 RAZ_Muir_Tobian_2023.pdf RAZ_Muir_Tobian_2023.pdf 1 12CF982475ED52E2696821292FA13431 ba2c1ec3b7b85c52025ac6483d1e0200ea0400a88ec3977f47ee073538ef4f88 8ce004d4-4a6e-11ef-b487-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=27501 Onkološki inštitut Ljubljana Društvo radiologije in onkologije 0 0 0